Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

Zhen Yuan; Shuyuan Wang; Kemin Ni; Yixiang Zhan; Hong Ma; Xinyu Liu; Ran Xin; Xingyu Zhou; Zhaoce Liu; Xuanzhu Zhao; Xin Yin; Hangyu Ping; Yaohong Liu; Wanting Wang; Suying Yan; Qiurong Han; Wei Cui; Xipeng Zhang; Qinghuai Zhang; Chunze Zhang

doi:10.12659/MSM.937757

19 September 2022 : Clinical Research

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

Zhen Yuan^12ABCDEF, Shuyuan Wang^12ABCDEF, Kemin Ni

^12ACDF, Yixiang Zhan^12ACDF, Hong Ma^1BDF, Xinyu Liu^13ABC, Ran Xin

^2ABC, Xingyu Zhou^2BC, Zhaoce Liu^12BC, Xuanzhu Zhao^14BC, Xin Yin^2BC, Hangyu Ping^2BC, Yaohong Liu^2BC, Wanting Wang^4BC, Suying Yan^4BC, Qiurong Han^4BC, Wei Cui

^5CD, Xipeng Zhang^167ADF, Qinghuai Zhang^167ABCD, Chunze Zhang^167ABCDEFG*

DOI: 10.12659/MSM.937757

Med Sci Monit 2022; 28:e937757

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Recurrence-free survival stratified by longitudinal mSEPT9 (A) and further stratified by chemotherapy regimens (FOLFOX/CAPEOX) in patients with longitudinal positive mSEPT9 (B) and in those with longitudinal negative mSEPT9 (C). (D) Comparison of time to recurrence detected by mSEPT9 and radiology (p<0.001). R software 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for Figure creation.

Back to the Article

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

Your Privacy